Bristol-Myers Squibb Company

Company: Bristol-Myers Squibb Company

Deadline: TBD

Kaskela Law LLC is investigating Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) of behalf of the Company’s stockholders.

On January 3, 2019, Bristol-Myers announced that it had entered into an agreement to acquire Celgene Corp. (Nasdaq: CELG).  According to the announcement, Bristol-Myers has proposed exchanging 1 share of Bristol-Myers common stock, $50 in cash, and one contingent value right (“CVR”) for each share of Celgene common stock.

In connection with the proposed acquisition, Bristol-Myers has disclosed that it expects to issue approximately 700 million shares of common stock to Celgene stockholders, and that it will need approximately $36 billion in order to pay Celgene stockholders the cash amounts due to them under the proposed transaction, and for related fees and transaction costs.

Kaskela Law’s investigation seeks to determine whether the proposed transaction as structured is fair to Bristol-Myers and its stockholders, and whether Bristol-Myers stockholders are being provided with all required material information necessary to evaluate and vote on the proposed transaction.

Bristol-Myers stockholders are encouraged to contact Kaskela Law at (888) 715 – 1740, or by completing the information form on this page, to discuss this investigation and their legal rights and options.

Submit Your Information

  • This field is for validation purposes and should be left unchanged.